Table 4 Adverse events reported in ⩾2% of the subjects in any treatment group

From: Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril

Adverse event

AZL-M 40

AZL-M 80

RAM 10

 

N=294

N=293

N=293

Any adverse event

112 (38.1)

128 (43.7)

113 (38.6)

Related to study druga

37 (12.6)

39 (13.3)

41 (14.0)

Leading to discontinuationb

7 (2.4)

9 (3.1)

14 (4.8)

Serious adverse event

8 (2.7)

12 (4.1)

6 (2.0)

Deaths

0

0

0

Events in ⩾2% of subjects

 Nasopharyngitis

19 (6.5)

13 (4.4)

17 (5.8)

 Headache

12 (4.1)

10 (3.4)

14 (4.8)

 Cough

3 (1.0)

4 (1.4)

24 (8.2)

 Increase in blood creatine kinase

6 (2.0)

9 (3.1)

4 (1.4)

 Dizziness

8 (2.7)

7 (2.4)

4 (1.4)

 Back pain

5 (1.7)

11 (3.8)

2 (0.7)

 Contusion

7 (2.4)

4 (1.4)

1 (0.3)

 Hypotension

4 (1.4)

6 (2.0)

2 (0.7)

 Increase in γ-glutamyl transferase

7 (2.4)

1 (0.3)

3 (1.0)

  1. Abbreviations: AZL-M, azilsartan medoxomil; RAM, ramipril.
  2. Data are n (%).
  3. aDefinitely, probably, or possibly related, as attributed by the investigator.
  4. bMight include temporary drug interruption or permanent discontinuation and includes all subjects who discontinued the study drug at least once.
Back to article page